Show simple item record

dc.contributor.authorAntolin, AA
dc.contributor.authorTym, JE
dc.contributor.authorKomianou, A
dc.contributor.authorCollins, I
dc.contributor.authorWorkman, P
dc.contributor.authorAl-Lazikani, B
dc.date.accessioned2017-11-23T12:46:24Z
dc.date.issued2018-02
dc.identifier.citationCell chemical biology, 2018, 25 (2), pp. 194 - 205.e5
dc.identifier.issn2451-9456
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/940
dc.identifier.eissn2451-9448
dc.identifier.doi10.1016/j.chembiol.2017.11.004
dc.description.abstractChemical probes are essential tools for understanding biological systems and for target validation, yet selecting probes for biomedical research is rarely based on objective assessment of all potential compounds. Here, we describe the Probe Miner: Chemical Probes Objective Assessment resource, capitalizing on the plethora of public medicinal chemistry data to empower quantitative, objective, data-driven evaluation of chemical probes. We assess >1.8 million compounds for their suitability as chemical tools against 2,220 human targets and dissect the biases and limitations encountered. Probe Miner represents a valuable resource to aid the identification of potential chemical probes, particularly when used alongside expert curation.
dc.formatPrint-Electronic
dc.format.extent194 - 205.e5
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectMolecular Probes
dc.subjectChemistry, Pharmaceutical
dc.subjectSmall Molecule Libraries
dc.titleObjective, Quantitative, Data-Driven Assessment of Chemical Probes.
dc.typeJournal Article
dcterms.dateAccepted2017-11-14
rioxxterms.funderThe Institute of Cancer Research
rioxxterms.identifier.projectUnspecified
rioxxterms.versionofrecord10.1016/j.chembiol.2017.11.004
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCell chemical biology
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2
pubs.publication-statusPublished
pubs.volume25
pubs.embargo.termsNot known
icr.researchteamComputational Biology and Chemogenomicsen_US
icr.researchteamMedicinal Chemistry 2en_US
dc.contributor.icrauthorKomianou, Angelikien
dc.contributor.icrauthorAl-Lazikani, Bissanen
dc.contributor.icrauthorWorkman, Paulen
dc.contributor.icrauthorCollins, Ianen
dc.contributor.icrauthorAntolin Hernandez, Alberten


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0